← LeaderboardsInvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Adjuvance Technologies, Inc.
New York, NY
$3,419,320
Total funding
4
Grants
Funding over time
peak $1.4M · FY2014–20$2M$1.5M$1M$500K$0
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$3,419,320 · 4
By mechanism
N43$1,694,321 · 2
R44$1,499,999 · 1
R43$225,000 · 1
Investigators at Adjuvance Technologies, Inc.
InvestigatorsiAttributed = a PI's even-split share of each grant — a $1M grant with 2 PIs counts $500K each.
Exposure= the full size of every grant they're on ($1M each).
Rising Stars
First grant in the last 5 yrs
Not enough data
Emerging Leaders
6–10 yrs in
Not enough data
All-Time
Most funded here, all years
Not enough data
Largest grants
Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine$1,427,022
N43 · FY2019 · AI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$756,567
R44 · FY2017 · AI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$743,432
R44 · FY2018 · AI
Large Scale Synthesis of the Next Generation Synthetic Saponin Adjuvant TiterQuil$225,000
R43 · FY2014 · AI
Determining the Impact of Semisynthetic Saponin Immunologic Adjuvant Titerquil-1055 on Influenza Vaccine Immunogenicity and Stability$223,002
N43 · FY2017 · AI
Preclinical development of semisynthetic saponin immunological adjuvant Titerquil-1055 in the context of an influenza vaccine$44,297
N43 · FY2020 · AI